<DOC>
	<DOCNO>NCT02110316</DOCNO>
	<brief_summary>The objective study obtain absolute bioavailability voriconazole critically ill ICU patient , pharmacokinetics different critically ill patient due alteration function various organ body system compare healthy volunteer .</brief_summary>
	<brief_title>Bioavailability Voriconazole</brief_title>
	<detailed_description>The bioavailability voriconazole , base healthy volunteer , estimate &gt; 90 % . Due high bioavailability voriconazole , switch oral intravenous administration permit clinically allow . Few data available bioavailability voriconazole critically ill patient . However , obtain therapeutic concentration voriconazole ( &gt; 1.5 mg/L , associate beneficial response treatment ) one study show high oral dose require compare intravenous dose , obtain therapeutic concentration . Therefore , pharmacokinetics change critically ill patient , include bioavailability . In study , patient receive voriconazole orally ( prescribed attend physician ) receive one intravenous dose voriconazole instead oral dose . The intravenous dose oral dose voriconazole .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Aged â‰¥ 18 yr ; Treatment voriconazole ; Admission ICU ; Written inform consent . Blood sample central venous catheter peripheral cannula possible ; Concomitantly use strong inhibitor inducer cytochrome P450 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>